BioCentury | Dec 17, 2007
Regulation

Atrial fibrillation pipeline

...potassium channel blocker AF Under review sanofi-aventis Multaq dronedarone Oral amiodarone analog AF Ph III Aderis...
BioCentury | Mar 6, 2006
Clinical News

Neupro rotigotine regulatory update

...in Phase III testing to treat restless legs syndrome (RLS), with data expected in 1Q07. Aderis Pharmaceuticals Inc....
BioCentury | Dec 19, 2005
Clinical News

Neupro rotigotine regulatory update

...patch to treat idiopathic Parkinson's disease (PD). Neupro is a dopamine D2 receptor agonist patch. Aderis Pharmaceuticals Inc....
BioCentury | Aug 15, 2005
Finance

Ebb & Flow

...companies included hematology and cancer company Pharmion (PHRM); cancer company Xanthus ; and neurological company Aderis...
BioCentury | Jul 25, 2005
Company News

Aderis, Schwarz Pharma deal

...Schwarz paid Aderis $67 million in cash to remove the royalties and milestones related to Neupro...
...to remove the royalties and milestones related to Neupro rotigotine that Schwarz would have owed Aderis...
...disease (PD). Neupro also is in Phase III testing to treat restless legs syndrome (RLS). Aderis Pharmaceuticals Inc....
BioCentury | Jul 25, 2005
Company News

Boston Life management update

...Mass. Business: Neurology, Diagnostic Hired: Noel Cusack as SVP of preclinical development, formerly CSO of Aderis Pharmaceuticals Inc....
...of finance and administration and in-house counsel, formerly VP, CFO and chief commercial officer of Aderis...
BioCentury | Jul 19, 2005
Company News

Boston Life Sciences names Rice CFO

...will remain VP and secretary. Previously, Rice was CFO, VP and chief commercial officer of Aderis...
BioCentury | Jan 10, 2005
Finance

Ebb & Flow

...cancer company Clavis Pharma and German stroke specialist Paion . U.S. investments include neurological company Aderis...
BioCentury | Jan 4, 2005
Financial News

First closing for NeoMed fund

...subsequent closings this summer. NeoMed's recent investments include Clavis Pharma (Oslo, Norway); Paion (Aachen, Germany); Aderis...
BioCentury | Oct 18, 2004
Product Development

A patch for Parkinson's

...release formulation of Mirapex is in Phase I. Rotigotine was in-licensed from Discovery Therapeutics Inc. (now Aderis Pharmaceuticals Inc....
...Schwarz licensed it to Otsuka Pharmaceutical Co. Ltd. (Tokyo, Japan) (see BioCentury, Nov. 18, 2002). Aderis...
Items per page:
1 - 10 of 75
BioCentury | Dec 17, 2007
Regulation

Atrial fibrillation pipeline

...potassium channel blocker AF Under review sanofi-aventis Multaq dronedarone Oral amiodarone analog AF Ph III Aderis...
BioCentury | Mar 6, 2006
Clinical News

Neupro rotigotine regulatory update

...in Phase III testing to treat restless legs syndrome (RLS), with data expected in 1Q07. Aderis Pharmaceuticals Inc....
BioCentury | Dec 19, 2005
Clinical News

Neupro rotigotine regulatory update

...patch to treat idiopathic Parkinson's disease (PD). Neupro is a dopamine D2 receptor agonist patch. Aderis Pharmaceuticals Inc....
BioCentury | Aug 15, 2005
Finance

Ebb & Flow

...companies included hematology and cancer company Pharmion (PHRM); cancer company Xanthus ; and neurological company Aderis...
BioCentury | Jul 25, 2005
Company News

Aderis, Schwarz Pharma deal

...Schwarz paid Aderis $67 million in cash to remove the royalties and milestones related to Neupro...
...to remove the royalties and milestones related to Neupro rotigotine that Schwarz would have owed Aderis...
...disease (PD). Neupro also is in Phase III testing to treat restless legs syndrome (RLS). Aderis Pharmaceuticals Inc....
BioCentury | Jul 25, 2005
Company News

Boston Life management update

...Mass. Business: Neurology, Diagnostic Hired: Noel Cusack as SVP of preclinical development, formerly CSO of Aderis Pharmaceuticals Inc....
...of finance and administration and in-house counsel, formerly VP, CFO and chief commercial officer of Aderis...
BioCentury | Jul 19, 2005
Company News

Boston Life Sciences names Rice CFO

...will remain VP and secretary. Previously, Rice was CFO, VP and chief commercial officer of Aderis...
BioCentury | Jan 10, 2005
Finance

Ebb & Flow

...cancer company Clavis Pharma and German stroke specialist Paion . U.S. investments include neurological company Aderis...
BioCentury | Jan 4, 2005
Financial News

First closing for NeoMed fund

...subsequent closings this summer. NeoMed's recent investments include Clavis Pharma (Oslo, Norway); Paion (Aachen, Germany); Aderis...
BioCentury | Oct 18, 2004
Product Development

A patch for Parkinson's

...release formulation of Mirapex is in Phase I. Rotigotine was in-licensed from Discovery Therapeutics Inc. (now Aderis Pharmaceuticals Inc....
...Schwarz licensed it to Otsuka Pharmaceutical Co. Ltd. (Tokyo, Japan) (see BioCentury, Nov. 18, 2002). Aderis...
Items per page:
1 - 10 of 75